Why Bausch + Lomb Stock Soared by Over 7% on Monday

It was quite a busy and eventful day for the company. Monday was an eventful day for Bausch + Lomb (BLCO 7.19%). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval. As if that weren't enough, media reports claimed that the company has put itself up for sale. Buffeted by these strong winds, Bausch + Lomb's stock price rose over 7% in the day's trading session. Eyes on the prize Of the two news items, the buyout one had the bigger i ...